Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

rituximab IV over 2-5 hours on days 1, 8, and 15

After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3

After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.

cyclophosphamide IV over 3-6 hours on day 16.

After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.

Patients then undergo peripheral blood stem cell (PBSC) collection.

Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.

Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.